This is critical information needed to survive a hospital visit for any reason. Be sure to watch the embedded video in the LifeSite article. Dr. Elizabeth Lee Vliet hosts various presenters in this Truth for Health Foundation press conference. This press conference reports that attorneys are working hard to get people out of hospitals in order to save their lives. Guests include LifeSite co-founder John-Henry Westen, attorney and patient advocate Ali Shultz, constitutional and civil rights attorney Lauren Martel, attorney Thomas Renz, and Dr. Peter McCullough.
Ali Shultz relates the challenges she faced in trying to advocate for her parents, even as a lawyer. It is crucial that certain legal documents be drawn up before any hospitalization including a medical power of attorney giving the most bad-ass member of your family the right to make decisions regarding your medical care. (You will NOT be able to make those decisions for yourself if you end up sedated and on a ventilator.)
Thomas Renz has promised criminal prosecution of those who have used the Remdesivir/ventilator protocol while excluding effective treatments.
Dr. Peter McCullough says that treatments exist that can keep just about any COVID patient out of the hospital. The key is prevention and early treatment. Everyone needs to be aware of methods for prevention and early treatment. Supplies need to be on hand at the time symptoms begin. Obtaining supplies can take time, so this is something to do right away, whether sick or not.
Sources:
- October 27, 2021. “‘Stop the Shot: Caught on Tape.’” LifeSite. Runtime of embedded video: 1:36:46.
https://www.lifesitenews.com/conference-stop-the-shot/stop-the-shot-caught-on-tape/.
News, Video. - October 27, 2021. Stop the Shot – Caught on Tape.. LeeVlietMD. Runtime: 1:30:43.
https://rumble.com/voboxj-stop-the-shot-caught-on-tape…html.
Video. - Truth for Health Foundation.
https://www.truthforhealth.org/.
Doctor Organization, Law, Activist. - “STEPS BEFORE HOSPITALIZATION.” Truth for Health Foundation.
https://www.truthforhealth.org/wp-content/uploads/2021/10/FACT-SHEET-STEPS-BEFORE-HOSPITALIZATION.pdf.
Doctor Organization, Law, Activist, PDF.
Remdesivir studies:
- December 12, 2019. Sabue Mulangu, Lori E. Dodd, Richard T. Davey, Olivier Tshiani Mbaya, Michael Proschan, Daniel Mukadi, Mariano Lusakibanza Manzo, Didier Nzolo, Antoine Tshomba Oloma, Augustin Ibanda, Rosine Ali, Sinaré Coulibaly, Adam C. Levine, Rebecca Grais, Janet Diaz, H. Clifford Lane, Jean-Jacques Muyembe-Tamfum, PALM Writing Group; Billy Sivahera, Modet Camara, Richard Kojan, Robert Walker, Bonnie Dighero-Kemp, Huyen Cao, Philippe Mukumbayi, Placide Mbala-Kingebeni, Steve Ahuka, Sarah Albert, Tyler Bonnett, Ian Crozier, Michael Duvenhage, Calvin Proffitt, Marc Teitelbaum, Thomas Moench, Jamila Aboulhab, Kevin Barrett, Kelly Cahill, Katherine Cone, Risa Eckes, Lisa Hensley, Betsey Herpin, Elizabeth Higgs, Julie Ledgerwood, Jerome Pierson, Mary Smolskis, Ydrissa Sow, John Tierney, Sumathi Sivapalasingam, Wendy Holman, Nikki Gettinger, David Vallée, Jacqueline Nordwall, and PALM Consortium Study Team. “A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.” The New England Journal of Medicine 381 (24): 2293–2303.
https://doi.org/10.1056/NEJMoa1910993.
Research Journal.
ZMapp and Remdesivir were eliminated from the study following an interim analysis during the trial for mortality reasons. Remdesivir was the most dangerous drug in that trial. This trial did not include a control. This trial was funded by NIAID. - June 11, 2020. Jonathan Grein, Norio Ohmagari, Daniel Shin, George Diaz, Erika Asperges, Antonella Castagna, Torsten Feldt, Gary Green, Margaret L. Green, François-Xavier Lescure, Emanuele Nicastri, Rentaro Oda, Kikuo Yo, Eugenia Quiros-Roldan, Alex Studemeister, John Redinski, Seema Ahmed, Jorge Bernett, Daniel Chelliah, Danny Chen, Shingo Chihara, Stuart H. Cohen, Jennifer Cunningham, Antonella D’Arminio Monforte, Saad Ismail, Hideaki Kato, Giuseppe Lapadula, Erwan L’Her, Toshitaka Maeno, Sumit Majumder, Marco Massari, Marta Mora-Rillo, Yoshikazu Mutoh, Duc Nguyen, Ewa Verweij, Alexander Zoufaly, Anu O. Osinusi, Adam DeZure, Yang Zhao, Lijie Zhong, Anand Chokkalingam, Emon Elboudwarej, Laura Telep, Leighann Timbs, Ilana Henne, Scott Sellers, Huyen Cao, Susanna K. Tan, Lucinda Winterbourne, Polly Desai, Robertino Mera, Anuj Gaggar, Robert P. Myers, Diana M. Brainard, Richard Childs, Timothy Flanigan. “Compassionate Use of Remdesivir for Patients with Severe Covid-19.” The New England Journal of Medicine 382 (24): 2327–36.
https://doi.org/10.1056/NEJMoa2007016.
Research Journal.
31% of patients had serious adverse events. (23% + 8%) The most common serious adverse events — multiple-organ-dysfunction syndrome, septic shock, acute kidney injury, and hypotension — were reported in patients who were receiving invasive ventilation at baseline. - September 2020. Marie Dubert, Benoit Visseaux, Valentina Isernia, Lila Bouadma, Laurène Deconinck, Juliette Patrier, Paul-Henri Wicky, Diane Le Pluart, Laura Kramer, Christophe Rioux, Quentin Le Hingrat, Nadhira Houhou-Fidouh, Yazdan Yazdanpanah, Jade Ghosn, Francois-Xavier Lescure. “Case Report Study of the First Five COVID-19 Patients Treated with Remdesivir in France.” International Journal of Infectious Diseases: IJID: Official Publication of the International Society for Infectious Diseases 98 (September): 290–93.
https://doi.org/10.1016/j.ijid.2020.06.093.
Research Journal.
Four of the trial patients had to be removed from the trial early: two because they were heading toward liver failure, and two because they had such severe kidney failure they they required transplants. Two of the trial patients ultimately died. France decided that Remdesivir was too dangerous to use in their country. - April 2021. Alexandre O. Gérard, Audrey Laurain, Audrey Fresse, Nadège Parassol, Marine Muzzone, Fanny Rocher, Vincent L. M. Esnault, and Milou-Daniel Drici. “Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database.” Clinical Pharmacology and Therapeutics 109 (4): 1021–24.
https://doi.org/10.1002/cpt.2145.
Research Journal.